State of the Art MR Imaging for Lung Cancer TNM Stage Evaluation

11Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

Abstract

Since the Radiology Diagnostic Oncology Group (RDOG) report had been published in 1991, magnetic resonance (MR) imaging had limited clinical availability for thoracic malignancy, as well as pulmonary diseases. However, technical advancements in MR systems, such as sequence and reconstruction methods, and adjustments in the clinical protocol for gadolinium contrast media administration have provided fruitful results and validated the utility of MR imaging (MRI) for lung cancer evaluations. These techniques include: (1) contrast-enhanced MR angiography for T-factor evaluation, (2) short-time inversion recovery turbo spin-echo sequences as well as diffusion-weighted imaging (DWI) for N-factor assessment, and (3) whole-body MRI with and without DWI and with positron emission tomography fused with MRI for M-factor or TNM stage evaluation as well as for postoperative recurrence assessment of lung cancer or other thoracic tumors using 1.5 tesla (T) or 3T systems. According to these fruitful results, the Fleischner Society has changed its position to approve of MRI for lung or thoracic diseases. The purpose of this review is to analyze recent advances in lung MRI with a particular focus on lung cancer evaluation, clinical staging, and recurrence assessment evaluation.

Author supplied keywords

Cite

CITATION STYLE

APA

Ohno, Y., Ozawa, Y., Koyama, H., Yoshikawa, T., Takenaka, D., Nagata, H., … Toyama, H. (2023, February 1). State of the Art MR Imaging for Lung Cancer TNM Stage Evaluation. Cancers. MDPI. https://doi.org/10.3390/cancers15030950

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free